What is FRC's Proprietary Fair Value Model?

FRC's Proprietary Fair Value Model is a premium feature built on Fundamental Research Corp's institutional-grade valuation methodology. This institutional-grade model combines fundamental analysis, financial modeling, and market metrics to determine a stock's intrinsic value. The model analyzes financial statements, earnings quality, growth rates, profitability ratios, and comparative valuations to calculate data-driven fair value estimates that professional investors trust for investment decisions. Available to premium subscribers.

What is Arch Biopartners Inc. stock price today?

Arch Biopartners Inc. (ARCH.V) is currently trading at $1.15 CAD on TSXV. Get real-time price updates, Snowflake performance analysis, and comprehensive financial statements. Premium subscribers can access fair value analysis using FRC's proprietary valuation model.

What does Arch Biopartners Inc. do?

Arch Biopartners Inc. operates in the Biotechnology sector within Healthcare. Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Met...

How do I analyze Arch Biopartners Inc. stock performance?

Our Snowflake Analysis provides a visual snapshot of Arch Biopartners Inc. performance across 5 key metrics: Past Performance, Revenue Growth, Profitability, Value, and Financial Health. Each metric is scored 1-5, with 5 being excellent performance. This multi-dimensional view helps investors quickly assess stock quality and compare performance against peers.

Where can I find Arch Biopartners Inc. financial statements?

Access Arch Biopartners Inc. complete financial statements including income statement, balance sheet, and cash flow statement in our comprehensive stock profile. Our platform provides detailed financial ratios, trend analysis, and institutional-grade financial analysis used by professional investors.

What makes FRC's stock analysis different from other platforms?

FRC applies its proprietary valuation model to public stock analysis, so fair value estimates rest on a rigorous, data-driven methodology rather than a consensus average. Our analysis includes real-time pricing, Snowflake performance metrics, comprehensive financial modeling, and research reports from professional analysts - providing institutional-grade insights for individual investors.

About Arch Biopartners Inc.

Industry

Biotechnology

Sector

Healthcare

CEO

Richard Gabriel Muruve

Headquarters

27 Street Clair Avenue East, Toronto, ON, CA

Industry

Biotechnology

Sector

Healthcare

CEO

Richard Gabriel Muruve

Headquarters

27 Street Clair Avenue East, Toronto, ON, CA

Description

Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, a drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The company is based in Toronto, Canada.

Arch Biopartners Inc.

ARCH.V•TSXV

Arch Biopartners Inc.

ARCH.V•TSXV

Market cap

$48.24M

Sentiment

Your view on ARCH.V

Mkt Cap

$48.24M

Sentiment

Your view

Company Overview

Overview

What the company does, where it operates, and who runs it.

About Arch Biopartners Inc.

Industry: Biotechnology
Sector: Healthcare
CEO: Richard Gabriel Muruve
Headquarters: 27 Street Clair Avenue East, Toronto, ON, CA

Industry: Biotechnology
Sector: Healthcare
CEO: Richard Gabriel Muruve
Headquarters: 27 Street Clair Avenue East, Toronto, ON, CA

Description

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

FRC's fair value estimate for Arch Biopartners Inc., and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Arch Biopartners Inc.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Arch Biopartners Inc.. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Arch Biopartners Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Arch Biopartners Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Arch Biopartners Inc. valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Which institutions hold Arch Biopartners Inc., and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

Buying and selling by Arch Biopartners Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Arch Biopartners Inc.. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Arch Biopartners Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Arch Biopartners Inc.. Press releases and market coverage, newest first.

News

Latest Market News